mRNA-based SARS-CoV-2 vaccines can induce protective immunity in older individuals, but whether they encompass new variants is not clear. Here the authors assess mRNA vaccine responses in both younger (<50) and older (>55) cohorts to find slightly delayed humoral and cellular immunity in the latter but, more importantly, reactivity to multiple variants.
(I understand an eTOC summary is provided, but unfortunately it does not conform with our format.)
- Mladen Jergović
- Jennifer L. Uhrlaub
- Janko Nikolich-Žugich